The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The researchers assessed the effect of Ox on objective and subjective speaking voice frequency in GH-treated girls with TS.

Who Took Part

PubMed indexes the participants as infants, young children, children and teenagers, women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and multicenter study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

A multicenter, randomized, placebo (Pl)-controlled, double-blind study was conducted.

Yearly from starting Ox/Pl until 6 months after discontinuing GH+Ox/Pl, voices were recorded and questionnaires were completed.

What Was Measured

PubMed files the paper under topics including Anabolic Agents, Estrogens, Growth Disorders, Hormone Replacement Therapy, Human Growth Hormone, Oxandrolone and Turner Syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2011 (Journal of voice : official journal of the Voice Foundation), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.